目的 探讨盘龙七片联合依托考昔治疗膝骨关节炎的临床效果。方法 选取2019年6月—2020年12月天津市第一中心医院收治的134例膝骨关节炎患者，随机分成对照组（67例）和治疗组（67例）。对照组口服依托考昔片，1片/次，1次/d。治疗组在对照组基础上口服盘龙七片，3片/次，3次/d。两组连续治疗8周。观察两组患者临床疗效，比较治疗前后两组患者主要症状与体征改善情况，膝骨性关节炎生存质量量表（QOL-KOA）评分，血清白细胞介素-1β（IL-1β）、基质金属蛋白酶-9（MMP-9）、血管内皮生长因子（VEGF）、转化生长因子β1（TGF-β1）、一氧化氮（NO）水平。结果 治疗后，治疗组总有效率为95.5%，明显高于对照组的85.1%（P＜0.05）。治疗后，两组患者膝关节疼痛视觉模拟量表（VAS）评分和西安大略和麦克马斯特大学骨关节炎指数（WOMAC）总分均显著低于同组治疗前（P＜0.05），晨僵时间显著短于治疗前（P＜0.05），且均以治疗组的改善更显著（P＜0.05）。治疗后，两组QOL-KOA中各项目评分及其总分均显著降低（P＜0.05），且治疗组的降低更显著（P＜0.05）。治疗后，两组血清IL-1β、MMP-9、VEGF和NO含量均显著低于同组治疗前，血清TGF-β1水平均显著高于本组治疗前（P＜0.05），且治疗组明显好于对照组（P＜0.05）。结论 盘龙七片联合依托考昔治疗膝骨关节炎的整体疗效满意，能安全有效地缓解患者症状与体征，提高生活质量。

Objective To investigate the clinical effect of Panlongqi Tablets combined with etoricoxib in treatment of knee osteoarthritis.Methods Patients (134 cases) with knee osteoarthritis in Tianjin First Central Hospital from June 2019 to December 2020 were randomly divided into control (67 cases) and treatment (67 cases) group. Patients in the control group were po administered with Etoricoxib Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Panlongqi Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, the improvement of main symptoms and signs, QOL-KOA scores, the levels of serum IL-1β, MMP-9, VEGF, TGF-β1 and NO in two groups before and after treatment were compared.Results After treatment, the total effective rate of the treatment group was 95.5%, which was significantly higher than that of the control group (85.1%) (P < 0.05). After treatment, the VAS score and the total score of WOMAC in two groups were significantly lower than those before treatment, and the time of morning stiffness in the treatment group was significantly shorter than that before treatment (P < 0.05), and the improvement in the treatment group was more significant (P < 0.05). After treatment, the scores of each item and the total score of QOL-KOA in two groups were significantly decreased (P < 0.05), especially in the treatment group (P < 0.05). After treatment, the levels of serum IL-1β, MMP-9, VEGF and NO in two groups were significantly lower than those before treatment, and the average level of serum TGF-β1 in two groups was significantly higher (P < 0.05), which in the treatment group were significantly better than the control group (P < 0.05).Conclusion The overall curative effect of Panlongqi Tablets combined with etoricoxib in treatment of knee osteoarthritis is satisfactory, which can safely and effectively alleviate the patients' symptoms and signs and improve the quality of life.

R977